Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation

David Wojciechowski, Flavio Vincenti

Research output: Contribution to journalReview article

15 Scopus citations

Abstract

Signaling through the costimulatory pathway is critical in the regulation of T cell activation. Abatacept, a selective costimulatory antagonist FDA approved for the treatment of moderate to severe rheumatoid arthritis, binds to CD80 and CD86 on antigen presenting cells, blocking the interaction with CD28 on T cells. Belatacept, a second generation CTLA4-Ig with 2 amino acid substitutions, has shown considerable promise in clinical transplantation as part of a maintenance immunosuppression regimen. This review will summarize the role of costimulation in T cell activation, detail the development of costimulation antagonists and highlight the pertinent clinical trials completed and ongoing utilizing belatacept as part of an immunosuppressive regimen in organ transplantation.

Original languageEnglish (US)
Pages (from-to)157-164
Number of pages8
JournalSeminars in Immunology
Volume23
Issue number3
DOIs
Publication statusPublished - Jun 1 2011
Externally publishedYes

    Fingerprint

Keywords

  • Belatacept
  • Costimulation
  • Kidney transplant

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this